CN112545980A - 低含量氟比洛芬酯药物组合物及其应用 - Google Patents
低含量氟比洛芬酯药物组合物及其应用 Download PDFInfo
- Publication number
- CN112545980A CN112545980A CN201910913849.0A CN201910913849A CN112545980A CN 112545980 A CN112545980 A CN 112545980A CN 201910913849 A CN201910913849 A CN 201910913849A CN 112545980 A CN112545980 A CN 112545980A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- flurbiprofen axetil
- injection
- content
- flurbiprofen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
处方 | 用量 | %(w/v) |
氟比洛芬酯 | 10g | 1 |
橄榄油 | 100g | 10 |
甘油 | 22.1g | 2.21 |
蛋黄卵磷脂 | 12g | 1.2 |
注射用水 | 加至1000ml |
处方 | 用量 | %(w/v) |
氟比洛芬酯 | 10g | 1 |
橄榄油 | 50g | 5 |
中链甘油三酯 | 50g | 5 |
甘油 | 22.1g | 2.21 |
蛋黄卵磷脂 | 12g | 1.2 |
注射用水 | 加至1000ml |
处方 | 用量 | %(w/v) |
氟比洛芬酯 | 10g | 1 |
大豆油 | 100g | 10 |
甘油 | 22.1g | 2.21 |
蛋黄卵磷脂 | 12g | 1.2 |
注射用水 | 加至1000ml |
处方 | 用量 | %(w/v) |
氟比洛芬酯 | 10g | 1 |
大豆油 | 100g | 10 |
甘油 | 22.1g | 2.21 |
蛋黄卵磷脂 | 12g | 1.2 |
注射用水 | 加至1000ml |
Claims (10)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910913849.0A CN112545980A (zh) | 2019-09-25 | 2019-09-25 | 低含量氟比洛芬酯药物组合物及其应用 |
US17/763,655 US20220331272A1 (en) | 2019-09-25 | 2020-09-22 | Pharmaceutical composition with low-content flurbiprofen axetil (fpa), and use thereof |
PCT/CN2020/116690 WO2021057694A1 (zh) | 2019-09-25 | 2020-09-22 | 低含量氟比洛芬酯药物组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910913849.0A CN112545980A (zh) | 2019-09-25 | 2019-09-25 | 低含量氟比洛芬酯药物组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112545980A true CN112545980A (zh) | 2021-03-26 |
Family
ID=75029452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910913849.0A Pending CN112545980A (zh) | 2019-09-25 | 2019-09-25 | 低含量氟比洛芬酯药物组合物及其应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20220331272A1 (zh) |
CN (1) | CN112545980A (zh) |
WO (1) | WO2021057694A1 (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103301063A (zh) * | 2013-06-14 | 2013-09-18 | 北京阜康仁生物制药科技有限公司 | S(+)-氟比洛芬酯注射乳剂 |
CN109985004A (zh) * | 2017-12-29 | 2019-07-09 | 北京蓝丹医药科技有限公司 | 氟比洛芬酯脂肪乳注射液、其制备方法及应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1621035A (zh) * | 2003-11-26 | 2005-06-01 | 梁建华 | 氟比洛芬酯注射药及其制备方法 |
CN103393631B (zh) * | 2013-08-22 | 2015-04-08 | 北京蓝丹医药科技有限公司 | 一种氟比洛芬酯药物组合物 |
CN104434798A (zh) * | 2014-12-18 | 2015-03-25 | 北京蓝丹医药科技有限公司 | 一种用于退热的氟比洛芬酯药物组合物 |
KR102421538B1 (ko) * | 2017-02-07 | 2022-07-14 | 큐피가부시키가이샤 | 지방 유제, 및 그 제조 방법, 지방 유제의 안정성을 향상시키는 방법, 그리고 지방 유제의 안정성 향상제 |
-
2019
- 2019-09-25 CN CN201910913849.0A patent/CN112545980A/zh active Pending
-
2020
- 2020-09-22 WO PCT/CN2020/116690 patent/WO2021057694A1/zh active Application Filing
- 2020-09-22 US US17/763,655 patent/US20220331272A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103301063A (zh) * | 2013-06-14 | 2013-09-18 | 北京阜康仁生物制药科技有限公司 | S(+)-氟比洛芬酯注射乳剂 |
CN109985004A (zh) * | 2017-12-29 | 2019-07-09 | 北京蓝丹医药科技有限公司 | 氟比洛芬酯脂肪乳注射液、其制备方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2021057694A1 (zh) | 2021-04-01 |
US20220331272A1 (en) | 2022-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4735967A (en) | Method for desensitizing the gastrointestinal tract from food allergies | |
CN1915222B (zh) | 一种脂质体组合物及其制备方法 | |
JP2002502870A (ja) | 炎症性状態処置のための方法および組成物 | |
Thimmasettaiah et al. | A prospective study to compare the effects of pre, intra and post operative steroid (dexamethasone sodium phosphate) on post tonsillectomy morbidity | |
Gloor et al. | Multiple cotton wool spots following bone marrow transplantation for treatment of acute lymphatic leukaemia. | |
NZ514536A (en) | Use of cetyl myristate and/or cetyl palmitate to treat asthma, chronic obstructive pulmonary disease and/or other respiratory difficulties | |
Garofalo et al. | Successful medical treatment for ranula in children | |
RU2322985C2 (ru) | Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости | |
JP2004520374A (ja) | 血圧降下剤としてのカロテノイド | |
JPH01265028A (ja) | 特発性血小板減少性紫斑病治療剤 | |
CN112545980A (zh) | 低含量氟比洛芬酯药物组合物及其应用 | |
LEIBOLD | Drugs having a toxic effect on the optic nerve | |
JP2022528566A (ja) | 眼疾患の処置方法 | |
CN110327319A (zh) | 一种治疗神经性皮炎的药物及其制备方法 | |
CN116036290A (zh) | 用于治疗皮肤病的联合疗法 | |
RU2611383C2 (ru) | Комбинированный препарат для устранения симптомов и лечения острых респираторных вирусных инфекций и гриппа | |
Bain et al. | The treatment of essential hypertension with pentolinium tartrate combined with Rauwolfia alkaloids | |
CN114177163B (zh) | 一种治疗高血压的药物 | |
RU2773682C1 (ru) | Применение фосфолипидной эмульсии, содержащей эффективное количество дигидрокверцетина, для лечения гестозов беременных первого триместра | |
CN117379448A (zh) | 神经节苷脂gm1在制备用于治疗脑卒中的药物中的用途 | |
Rajshekher | Recent trends in the management of status epilepticus | |
JPH10158193A (ja) | 鼻炎治療用組成物 | |
CN1227109A (zh) | 一种抗动脉粥样硬化的药 | |
TW202202168A (zh) | 用於改善玻璃體混濁的組成物及其應用 | |
Larson Jr et al. | Maternally administered esmolol decreases fetal as well as maternal heart rate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210423 Address after: 226123 No.18, Qinghua Road, Sanchang street, Haimen District, Nantong City, Jiangsu Province Applicant after: Jiangsu Huiju Pharmaceutical Co.,Ltd. Address before: 101111 Beijing city Daxing District Branch Street No. 88 Yizhuang biomedical park, building 1508 room Applicant before: BEIJING PUDEKANGLI PHARMACEUTICAL TECHNOLOGY DEVELOPMENT Co.,Ltd. |
|
TA01 | Transfer of patent application right | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 226123 No.18, Qinghua Road, Sanchang street, Haimen District, Nantong City, Jiangsu Province Applicant after: Jiangsu Huiju Pharmaceutical Co.,Ltd. Address before: 226123 No.18, Qinghua Road, Sanchang street, Haimen District, Nantong City, Jiangsu Province Applicant before: Jiangsu Huiju Pharmaceutical Co.,Ltd. |
|
CB02 | Change of applicant information | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210326 |
|
RJ01 | Rejection of invention patent application after publication |